Document text
Principal Investigator: Nicole Doria-Rose
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $1,368,169
Funding agency: National Institute of Allergy and Infectious Diseases
During the past years, the Virology Laboratory has collaborated with other intramural NIAID labs and other external collaborators to develop a pseudovirus neutralization assay and an mRNA vaccine expressing the prefusion-stabilized SARS-CoV-2 spike trimer (mRNA-1273). For the neutralization assay, we have provided technical and software assistance to other VRC labs,and developed a shared Standard Operating Procedure. Since more new SARS-CoV-2 variant viruses continuously arise in the world, we are continuously making various pseudoviruses corresponding to the emerging variants. And more importantly, the pseudovirus neutralization assay also needed to be modified to adapted to the new variants for the assay appropriate usage. The assay is being used by laboratory staff to evaluate human serum samples from individuals recovering from COVID-19 and from volunteers in the clinical trial of the government approved vaccines. We are also isolating and characterizing monoclonal antibodies from individuals recovering from COVID-19 disease and/or receiving several doses of vaccines, assessing for SARS-CoV-2 neutralizing antibodies, which are valuable research reagents with great potential for therapeutic and prevention purposes against the continuously emerging SARS-CoV-2 variants.
By using this powerful assay, we have analyzed the potency and cross-reactivity of anti-COVID-19 antibodies in the blood of vaccinated or infected individuals. Specifically, we have measured neutralizing antibodies against the original or SARS-CoV-2 variants as part of clinical trials for mRNA vaccines. We have also assessed the neutralization activity of monoclonal antibodies isolated from individuals who have recovered from COVID-19, as part of our basic research on viral immunity, and in search of monoclonal antibodies with preventative or therapeutic potential.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><Animals><Assay><Basic Research><Basic Science><Bioassay><Biological Assay><Blood><Blood Reticuloendothelial System><Blood Serum><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19 virus><CV-19><Clinical Treatment Moab><Clinical Trials><CoV-2><CoV2><Collaborations><Computer software><Coronavirus Infectious Disease 2019><Disease><Disorder><Dose><Government><Human><Immunity><Immunize><Immunology procedure><Individual><Laboratories><Measures><Modern Man><Moderna COVID-19 vaccine><Moderna coronavirus disease 2019 vaccine><Monoclonal Antibodies><NIAID><National Institute of Allergy and Infectious Disease><Prevention><Procedures><RNA vaccine><RNA-based vaccine><Reagent><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Serum><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome related corona virus 2><Software><Spikevax><Therapeutic><Vaccinated><Vaccines><Variant><Variation><Viral><Virus><Wuhan coronavirus><antibody against COVID-19><antibody against SARS-CoV-2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><cross reactivity><evaluate vaccines><hCoV19><human subject><immunologic assay><immunologic assay/test><isolated individuals><isolated people><lonely individuals><lonely people><mAbs><mRNA vaccine><mRNA-1273><mRNA-based vaccine><mRNA1273><monoclonal Abs><nCoV2><neutralizing antibody><pre-clinical><preclinical><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><spike proteins on SARS-CoV-2><vaccine candidate><vaccine evaluation><vaccine screening><vaccine testing><virology><volunteer>